1
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


2
Philip L Felgner, Jon A Wolff, Gary H Rhodes, Robert W Malone, Dennis A Carson: Delivery of exogenous DNA sequences in a mammal. VICAL Incorporated, Wisconsin Alumni Research Foundation, Knobbe Martens Olson & Bear, December 3, 1996: US05580859 (762 worldwide citation)

Polynucleotide sequences, comprising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynucleotides can be contained within liposomes or the polynucleotides can free from associatio ...


3
Jack S Cohen, Len Neckers, Cy Stein, She L Loke, Kazuo Shinozuka: Inhibitors for replication of retroviruses and for the expression of oncogene products. The United States of America represented by the Department of Health and Human Services, Townsend and Townsend Khourie and Crew, November 23, 1993: US05264423 (383 worldwide citation)

Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.


4
Jack S Cohen, Len Neckers, Cy Stein, She L Loke, Kazuo Shinozuka: Inhibitors for replication of retroviruses and for the expression of oncogene products. The United States of America represented by the Department of Health and Human Services, Townsend and Townsend Khourie and Crew, February 15, 1994: US05286717 (298 worldwide citation)

Phosphorothioate oligodeoxyribonucleotide analogs can be used to prevent replication of foreign nucleic acids in the presence of normal living cells, as well as to inhibit the proliferation of neoplastic cells.


5
Ruey J Yu, Eugene J Van Scott: Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use. Foley & Lardner, February 25, 1992: US05091171 (297 worldwide citation)

Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatol ...


6
Endre A Balazs: Ultrapure hyaluronic acid and the use thereof. Biotrics, Hubbell Cohen Stiefel & Gross, February 27, 1979: US04141973 (297 worldwide citation)

An ultra-pure, high molecular weight hyaluronic acid fraction which is characterized by the absence of significant cellular infiltration of the vitreous and anterior chamber, absence of significant flare in the aqueous humor, absence of significant haze or flare in the vitreous and absence of pathol ...


7
Philip D Cook, Yogesh S Sanghvi: Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression. Isis Pharmaceuticals, Woodcock Washburn Kurtz Mackiewicz & Norris, March 25, 1997: US05614617 (280 worldwide citation)

Oligonucleotide analogs are provided having improved nuclease resistance. Modifications of selected nucleotides through substitutions on the pyrimidine ring are disclosed. Certain preferred embodiments comprise the inclusion of said modified nucleotides at a plurality of sites, especially at the 3' ...


8
Mark Matteucci, Robert J Jones, John Munger: Modified internucleoside linkages having one nitrogen and two carbon atoms. Gilead Sciences, Daryl D Muenchau, January 21, 1997: US05596086 (277 worldwide citation)

Oligonucleotide analogs are disclosed wherein one or more phosphodiester linkages between adjacent nucleotides are replaced by a backbone linkage resistant to nucleases. The modified oligonucleotides are capable of strong hybridization to target RNA or DNA. The oligomers of the invention may be used ...


9
Charlotte A Kensil, Dante J Marciani: Saponin adjuvant. Cambridge Biotech Corporation, Sterne Kessler Goldstein & Fox, October 15, 1991: US05057540 (271 worldwide citation)

Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.


10
Josef Pitha: Pharmaceutical preparations containing cyclodextrin derivatives. The United States of America represented by the Department of Health and Human Services, John S Roberts Jr, February 23, 1988: US04727064 (270 worldwide citation)

The invention comprises pharmaceutical preparations consisting generally of a drug with a substantially low water solubility and an amorphous, water-soluble cyclodextrin-based mixtures. In these preparations a stable amorphous state can be achieved. This improves the dissolution properties of the dr ...